WCAMG
NAGE

Woodard & Company Asset Management Group’s Niagen Bioscience NAGE Stock Holding History

Woodard & Company Asset Management Group’s Portfolio NAGE Stock Details NAGE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-10,000
Closed -$42K – 31
2019
Q1 		$42K Buy
+10,000
New +$36.1K 0.35% 25

Other funds holding NAGE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Iconiq Capital San Francisco, California $4.46B AUM 22.86% 1-Year Est. Return
TCM
Tieton Capital Management Yakima, Washington $299M AUM 54.55% 1-Year Est. Return
UIC
Uniplan Investment Counsel Milwaukee, Wisconsin $974M AUM 21.37% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
JMPWA
JP Morgan Private Wealth Advisors San Francisco, California $35B AUM 24.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Woodard & Company Asset Management Group's NAGE Position: Q2 2019 in Review

Woodard & Company Asset Management Group sold out of Niagen Bioscience (NAGE) in Q2 2019, closing a stake of 10,000 shares — an estimated $42K sold.

Woodard & Company Asset Management Group first reported a position in NAGE in Q1 2019 and held it in 1 quarter. The position peaked at $42K in Q1 2019. 58 funds tracked by Wall St. Rank hold NAGE as of Q2 2019.

  • Woodard & Company Asset Management Group reported no remaining Niagen Bioscience position as of Q2 2019 after selling out during the quarter.
  • Woodard & Company Asset Management Group sold 10,000 Niagen Bioscience shares in Q2 2019, an estimated $42K.
  • Woodard & Company Asset Management Group first reported a position in Niagen Bioscience in Q1 2019 and held it in 1 quarter.
  • Woodard & Company Asset Management Group's Niagen Bioscience position peaked at $42K in Q1 2019.
  • 58 funds tracked by Wall St. Rank held Niagen Bioscience as of Q2 2019.

Based on Woodard & Company Asset Management Group's 13F filing for Q2 2019, filed 26 Jul 2019.